tetano
Editor, Senior Moderator
Cell
. 2022 Jan 25;S0092-8674(22)00076-9.
doi: 10.1016/j.cell.2022.01.018. Online ahead of print.
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
Katharina Röltgen[SUP] 1 [/SUP], Sandra C A Nielsen[SUP] 1 [/SUP], Oscar Silva[SUP] 1 [/SUP], Sheren F Younes[SUP] 1 [/SUP], Maxim Zaslavsky[SUP] 1 [/SUP], Cristina Costales[SUP] 1 [/SUP], Fan Yang[SUP] 1 [/SUP], Oliver F Wirz[SUP] 1 [/SUP], Daniel Solis[SUP] 1 [/SUP], Ramona A Hoh[SUP] 1 [/SUP], Aihui Wang[SUP] 1 [/SUP], Prabhu S Arunachalam[SUP] 2 [/SUP], Deana Colburg[SUP] 1 [/SUP], Shuchun Zhao[SUP] 1 [/SUP], Emily Haraguchi[SUP] 1 [/SUP], Alexandra S Lee[SUP] 3 [/SUP], Mihir M Shah[SUP] 3 [/SUP], Monali Manohar[SUP] 3 [/SUP], Iris Chang[SUP] 3 [/SUP], Fei Gao[SUP] 2 [/SUP], Vamsee Mallajosyula[SUP] 2 [/SUP], Chunfeng Li[SUP] 2 [/SUP], James Liu[SUP] 4 [/SUP], Massa J Shoura[SUP] 1 [/SUP], Sayantani B Sindher[SUP] 3 [/SUP], Ella Parsons[SUP] 3 [/SUP], Naranjargal J Dashdorj[SUP] 5 [/SUP], Naranbaatar D Dashdorj[SUP] 6 [/SUP], Robert Monroe[SUP] 7 [/SUP], Geidy E Serrano[SUP] 8 [/SUP], Thomas G Beach[SUP] 8 [/SUP], R Sharon Chinthrajah[SUP] 9 [/SUP], Gregory W Charville[SUP] 1 [/SUP], James L Wilbur[SUP] 10 [/SUP], Jacob N Wohlstadter[SUP] 10 [/SUP], Mark M Davis[SUP] 11 [/SUP], Bali Pulendran[SUP] 12 [/SUP], Megan L Troxell[SUP] 1 [/SUP], George B Sigal[SUP] 10 [/SUP], Yasodha Natkunam[SUP] 1 [/SUP], Benjamin A Pinsky[SUP] 13 [/SUP], Kari C Nadeau[SUP] 9 [/SUP], Scott D Boyd[SUP] 14 [/SUP]
Affiliations
Abstract
During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been deployed globally. We investigated whether antibodies stimulated by mRNA vaccination (BNT162b2), including third-dose boosting, differ from those generated by infection or adenoviral (ChAdOx1-S and Gam-COVID-Vac) or inactivated viral (BBIBP-CorV) vaccines. We analyzed human lymph nodes after infection or mRNA vaccination for correlates of serological differences. Antibody breadth against viral variants is lower after infection compared with all vaccines evaluated but improves over several months. Viral variant infection elicits variant-specific antibodies, but prior mRNA vaccination imprints serological responses toward Wuhan-Hu-1 rather than variant antigens. In contrast to disrupted germinal centers (GCs) in lymph nodes during infection, mRNA vaccination stimulates robust GCs containing vaccine mRNA and spike antigen up to 8 weeks postvaccination in some cases. SARS-CoV-2 antibody specificity, breadth, and maturation are affected by imprinting from exposure history and distinct histological and antigenic contexts in infection compared with vaccination.
Keywords: Astra Zeneca; BBIBP-CorV; BNT162b2; BioNTech-Pfizer; COVID-19; ChAdOx1-S; Delta variant; Gam-COVID-Vac; Moderna; SARS-CoV-2; SARS-CoV-2 variants of concern; Sinopharm; Sputnik V; antibodies; autopsy; endemic coronaviruses; imprinting; lymph node germinal center; mRNA-1273; vaccine.
. 2022 Jan 25;S0092-8674(22)00076-9.
doi: 10.1016/j.cell.2022.01.018. Online ahead of print.
Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination
Katharina Röltgen[SUP] 1 [/SUP], Sandra C A Nielsen[SUP] 1 [/SUP], Oscar Silva[SUP] 1 [/SUP], Sheren F Younes[SUP] 1 [/SUP], Maxim Zaslavsky[SUP] 1 [/SUP], Cristina Costales[SUP] 1 [/SUP], Fan Yang[SUP] 1 [/SUP], Oliver F Wirz[SUP] 1 [/SUP], Daniel Solis[SUP] 1 [/SUP], Ramona A Hoh[SUP] 1 [/SUP], Aihui Wang[SUP] 1 [/SUP], Prabhu S Arunachalam[SUP] 2 [/SUP], Deana Colburg[SUP] 1 [/SUP], Shuchun Zhao[SUP] 1 [/SUP], Emily Haraguchi[SUP] 1 [/SUP], Alexandra S Lee[SUP] 3 [/SUP], Mihir M Shah[SUP] 3 [/SUP], Monali Manohar[SUP] 3 [/SUP], Iris Chang[SUP] 3 [/SUP], Fei Gao[SUP] 2 [/SUP], Vamsee Mallajosyula[SUP] 2 [/SUP], Chunfeng Li[SUP] 2 [/SUP], James Liu[SUP] 4 [/SUP], Massa J Shoura[SUP] 1 [/SUP], Sayantani B Sindher[SUP] 3 [/SUP], Ella Parsons[SUP] 3 [/SUP], Naranjargal J Dashdorj[SUP] 5 [/SUP], Naranbaatar D Dashdorj[SUP] 6 [/SUP], Robert Monroe[SUP] 7 [/SUP], Geidy E Serrano[SUP] 8 [/SUP], Thomas G Beach[SUP] 8 [/SUP], R Sharon Chinthrajah[SUP] 9 [/SUP], Gregory W Charville[SUP] 1 [/SUP], James L Wilbur[SUP] 10 [/SUP], Jacob N Wohlstadter[SUP] 10 [/SUP], Mark M Davis[SUP] 11 [/SUP], Bali Pulendran[SUP] 12 [/SUP], Megan L Troxell[SUP] 1 [/SUP], George B Sigal[SUP] 10 [/SUP], Yasodha Natkunam[SUP] 1 [/SUP], Benjamin A Pinsky[SUP] 13 [/SUP], Kari C Nadeau[SUP] 9 [/SUP], Scott D Boyd[SUP] 14 [/SUP]
Affiliations
- PMID: 35148837
- DOI: 10.1016/j.cell.2022.01.018
Abstract
During the SARS-CoV-2 pandemic, novel and traditional vaccine strategies have been deployed globally. We investigated whether antibodies stimulated by mRNA vaccination (BNT162b2), including third-dose boosting, differ from those generated by infection or adenoviral (ChAdOx1-S and Gam-COVID-Vac) or inactivated viral (BBIBP-CorV) vaccines. We analyzed human lymph nodes after infection or mRNA vaccination for correlates of serological differences. Antibody breadth against viral variants is lower after infection compared with all vaccines evaluated but improves over several months. Viral variant infection elicits variant-specific antibodies, but prior mRNA vaccination imprints serological responses toward Wuhan-Hu-1 rather than variant antigens. In contrast to disrupted germinal centers (GCs) in lymph nodes during infection, mRNA vaccination stimulates robust GCs containing vaccine mRNA and spike antigen up to 8 weeks postvaccination in some cases. SARS-CoV-2 antibody specificity, breadth, and maturation are affected by imprinting from exposure history and distinct histological and antigenic contexts in infection compared with vaccination.
Keywords: Astra Zeneca; BBIBP-CorV; BNT162b2; BioNTech-Pfizer; COVID-19; ChAdOx1-S; Delta variant; Gam-COVID-Vac; Moderna; SARS-CoV-2; SARS-CoV-2 variants of concern; Sinopharm; Sputnik V; antibodies; autopsy; endemic coronaviruses; imprinting; lymph node germinal center; mRNA-1273; vaccine.